Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 3/2010

01-12-2010 | Case Report

Misdiagnosis of Niemann-Pick disease type C as Gaucher disease

Authors: Sarah M. Lo, Joseph McNamara, Margherita R. Seashore, Pramod K. Mistry

Published in: Journal of Inherited Metabolic Disease | Special Issue 3/2010

Login to get access

Abstract

Niemann-Pick disease type C (NPC) is a model for inborn errors of metabolism whose gene product mediates molecular trafficking rather than catabolizing macromolecules, as in classic lipidoses. We report the case of an infant who presented with hepatosplenomegaly without neurological abnormalities. Decreased activity of acid β-glucosidase and elevated serum chitotriosidase and tartrate-resistant acid phosphatase on repeated measurements led to initial diagnosis of Gaucher disease (GD). Failure to respond to enzyme replacement therapy after one year, however, put the diagnosis in question. Cholesterol esterification assays in cultured skin fibroblasts and NPC gene analysis led to the correct diagnosis of NPC. The patient had markedly reduced cholesterol esterification and was a compound heterozygote for a known and a novel mutation in the NPC gene (395delC and 2068insTCCC), which are both predicted to lead to protein truncation. Although the full phenotype of NPC involves hepatosplenomegaly and neurodegenerative disease, the initial presentation in a pediatric patient may be restricted to visceral disease. Of interest, this patient had decreased activity of leukocyte acid β-glucosidase activity and elevated serum chitotriosidase to levels often seen in GD. Although acid β-glucosidase activity in leukocytes was low, it was in the normal range in skin fibroblasts. Therefore, diagnostic delay may occur in NPC due to false positive testing for GD. Diagnosis of NPC requires a high index of suspicion and should be considered in a patient with hepatosplenomegaly even in the absence of neurodevelopmental signs. Prompt diagnosis will become increasingly important as effective therapies are developed for NPC.
Literature
go back to reference Aerts JMFG, Hollak CEM, Boot RG, Groener JEM, Maas M (2006) Substrate reduction therapy of glycosphingolipid disorders. J Inherit Metab Dis 29:449–456PubMedCrossRef Aerts JMFG, Hollak CEM, Boot RG, Groener JEM, Maas M (2006) Substrate reduction therapy of glycosphingolipid disorders. J Inherit Metab Dis 29:449–456PubMedCrossRef
go back to reference Beutler E, Kuhl W (1970) Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes. Lancet 1(7647):612–613PubMedCrossRef Beutler E, Kuhl W (1970) Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes. Lancet 1(7647):612–613PubMedCrossRef
go back to reference Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372(9645):1263–1271PubMedCrossRef Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372(9645):1263–1271PubMedCrossRef
go back to reference Guo Y, He W, Boer AM et al (1995) Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 18:717–722PubMedCrossRef Guo Y, He W, Boer AM et al (1995) Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 18:717–722PubMedCrossRef
go back to reference Kacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, Silman I, Sussman JL, Futerman AH (2008) Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy. Biol Chem 389(11):1361–1369, ReviewPubMedCrossRef Kacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, Silman I, Sussman JL, Futerman AH (2008) Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy. Biol Chem 389(11):1361–1369, ReviewPubMedCrossRef
go back to reference Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE (2009) Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137(7):1213–1224PubMedCrossRef Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE (2009) Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137(7):1213–1224PubMedCrossRef
go back to reference Lloyd-Evans E, Platt FM (2010) Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic. [Epub ahead of print] Lloyd-Evans E, Platt FM (2010) Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic. [Epub ahead of print]
go back to reference Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, Churchill GC, Schuchman EH, Galione A, Platt FM (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 14(11):1247–1255PubMedCrossRef Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, Churchill GC, Schuchman EH, Galione A, Platt FM (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 14(11):1247–1255PubMedCrossRef
go back to reference NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topçu M, Vanier MT, Widner H, Wijburg FA, Patterson MC (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98(1–2):152–165PubMedCrossRef NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topçu M, Vanier MT, Widner H, Wijburg FA, Patterson MC (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98(1–2):152–165PubMedCrossRef
go back to reference Patterson MC (2003) A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurologist 6:301–310CrossRef Patterson MC (2003) A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurologist 6:301–310CrossRef
go back to reference Patterson MC, Vanier MT, Suzuki K et al (2001) Niemann-Pick disease, type C: a lipid trafficking disorder. In: Beaudet AL, Sly WS, Valle D et al (eds) The metabolic and molecular bases of inherited disease, Vol. 3, 8th edn. McGraw-Hill, New York, pp 3611–3633 Patterson MC, Vanier MT, Suzuki K et al (2001) Niemann-Pick disease, type C: a lipid trafficking disorder. In: Beaudet AL, Sly WS, Valle D et al (eds) The metabolic and molecular bases of inherited disease, Vol. 3, 8th edn. McGraw-Hill, New York, pp 3611–3633
go back to reference Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann–Pick C disease: a randomized controlled study. Lancet Neurol 6:765–772, S1474-4422(07)70194-1PubMedCrossRef Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann–Pick C disease: a randomized controlled study. Lancet Neurol 6:765–772, S1474-4422(07)70194-1PubMedCrossRef
go back to reference Puri V, Watanabe R, Dominguez M, Sun X, Wheatley CL, Marks DL, Pagano RE (1999) Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol 1:386–388PubMedCrossRef Puri V, Watanabe R, Dominguez M, Sun X, Wheatley CL, Marks DL, Pagano RE (1999) Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol 1:386–388PubMedCrossRef
go back to reference Puri V, Jefferson JR, Singh RD, Wheatley CL, Marks DL, Pagano RE (2003) Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J Biol Chem 278(23):20961–20970PubMedCrossRef Puri V, Jefferson JR, Singh RD, Wheatley CL, Marks DL, Pagano RE (2003) Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J Biol Chem 278(23):20961–20970PubMedCrossRef
go back to reference Ries M, Schaefer E, Lührs T, Mani L, Kuhn J, Vanier MT, Krummenauer F, Gal A, Beck M, Mengel E (2006) Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C. J Inherit Metab Dis 29:647–652PubMedCrossRef Ries M, Schaefer E, Lührs T, Mani L, Kuhn J, Vanier MT, Krummenauer F, Gal A, Beck M, Mengel E (2006) Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C. J Inherit Metab Dis 29:647–652PubMedCrossRef
go back to reference Salvioli R, Scarpa S, Ciaffoni F, Tatti M, Ramoni C, Vanier MT, Vaccaro AM (2004) Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C. J Biol Chem 279(17):17674–17680PubMedCrossRef Salvioli R, Scarpa S, Ciaffoni F, Tatti M, Ramoni C, Vanier MT, Vaccaro AM (2004) Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C. J Biol Chem 279(17):17674–17680PubMedCrossRef
go back to reference Santos ML, Raskin S, Telles DS et al (2008) Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: A case report in Brazil. J Inherit Metab Dis: Epub ahead of print Oct 21 Santos ML, Raskin S, Telles DS et al (2008) Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: A case report in Brazil. J Inherit Metab Dis: Epub ahead of print Oct 21
go back to reference Sun X, Marks DL, Park WD, Wheatley CL, Puri V, O'Brien JF, Kraft DL, Lundquist PA, Patterson MC, Pagano RE, Snow K (2001) Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet 68(6):1361–1372PubMedCrossRef Sun X, Marks DL, Park WD, Wheatley CL, Puri V, O'Brien JF, Kraft DL, Lundquist PA, Patterson MC, Pagano RE, Snow K (2001) Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet 68(6):1361–1372PubMedCrossRef
go back to reference Tang Y, Li H, Liu JP (2009) Niemann-Pick Disease type C: from molecule to clinic. Clin Exp Pharmacol Physiol 37(1):132–140PubMedCrossRef Tang Y, Li H, Liu JP (2009) Niemann-Pick Disease type C: from molecule to clinic. Clin Exp Pharmacol Physiol 37(1):132–140PubMedCrossRef
go back to reference Vanier MT (1983) Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta 750:178–184PubMedCrossRef Vanier MT (1983) Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta 750:178–184PubMedCrossRef
go back to reference Vanier MT (1999) Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res 24:481–489PubMedCrossRef Vanier MT (1999) Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res 24:481–489PubMedCrossRef
go back to reference Wajner A, Michelin K, Burin MG, Pires RF, Pereira MLS, Giugliani R, Coelho JC (2004) Biochemical characterization of chitotriosidase enzyme: comparison between normal individuals and patients with Gaucher and with Niemann-Pick diseases. Clin Biochem 37:893–897PubMedCrossRef Wajner A, Michelin K, Burin MG, Pires RF, Pereira MLS, Giugliani R, Coelho JC (2004) Biochemical characterization of chitotriosidase enzyme: comparison between normal individuals and patients with Gaucher and with Niemann-Pick diseases. Clin Biochem 37:893–897PubMedCrossRef
go back to reference Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S (2008) A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 83(12):890–895PubMedCrossRef Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S (2008) A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 83(12):890–895PubMedCrossRef
go back to reference Zervas M, Somers KL, Thrall MA, Walkley SU (2001) Critical role of glycosphingolipids in Niemann-Pick disease type C. Curr Biol 11:1283–1287PubMedCrossRef Zervas M, Somers KL, Thrall MA, Walkley SU (2001) Critical role of glycosphingolipids in Niemann-Pick disease type C. Curr Biol 11:1283–1287PubMedCrossRef
Metadata
Title
Misdiagnosis of Niemann-Pick disease type C as Gaucher disease
Authors
Sarah M. Lo
Joseph McNamara
Margherita R. Seashore
Pramod K. Mistry
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 3/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9214-3

Other articles of this Special Issue 3/2010

Journal of Inherited Metabolic Disease 3/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.